2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159675
    1-A-N 98%
    1-A-N is a lipid nanoparticle (LNP) used for in vivo delivery of siRNA. 1-A-N can regulate immune response by delivering siCD45 (siRNA targeting CD45) to T cells and silencing the CD45 gene.
    1-A-N
  • HY-159718
    NLRP3-IN-46 98%
    NLRP3-IN-46 (Compound 3k) activates neuro-immunomodulatory cholinergic anti-inflammatory pathway, and thus inhibits NLRP3 inflammasome activation. NLRP3-IN-46 inhibits Uric acid sodium (HY-B2130A)-induced IL-1β production in THP-1 cells, and can be used in gouty arthritis research.
    NLRP3-IN-46
  • HY-159743
    M101 98%
    M101 is a vaccine adjuvant. Its main component is highly purified immunologically active substances with a pH value ranging from 4.0 to 6.5. This adjuvant is safe, non-toxic and metabolizable, and can effectively induce immune responses in the body. It has strong immune effects on both T-cell-dependent and T-cell-independent antigens. This adjuvant is applicable to various veterinary vaccines and is recommended for use in porcine circovirus.
    M101
  • HY-159744
    Liposomal adjuvant (M103) 98%
    Liposomal adjuvant (M103) is mainly composed of phospholipids and prepared with highly purified immunostimulatory substances (polysaccharides), with a pH value of 6.2-6.8. This adjuvant is safe, non-toxic, and metabolizable. It can induce cellular and humoral immunity, has a sustained-release effect, and can prolong the residence time of antigens in the body. This adjuvant is suitable for various veterinary vaccines, including inactivated vaccines and genetically engineered subunit vaccines. It is recommended for use in rabies, porcine circovirus, , foot-and-mouth disease (FMD), and blue ear disease, etc.
    Liposomal adjuvant (M103)
  • HY-159749
    M902 98%
    M902 is a new type of mineral oil-based adjuvant, which belongs to oil-in-water (O/W) emulsion. It rapidly stimulates the body to produce an immune response, has a low oil content, high safety, can induce natural immune responses, improve the efficiency of antigen uptake and presentation, induce the production of various cytokines, and increase the level of specific antibodies against antigens in the animal body. It is applicable to various veterinary vaccines, including inactivated vaccines and genetically engineered subunit vaccines, such as vaccine for Porcine Circovirus and Mycoplasma Hyopneumoniae.
    M902
  • HY-159750
    M903 98%
    M903 is a new type of mineral oil-based adjuvant, which belongs to water-in-oil-in-water (w/o/w) emulsion. It can enhance both cellular and humoral immunity against non-specific antigens, stimulate specific immunity against the antigens, delay the release of the antigens in the body, and improve the immunity of animals. It is applicable to various veterinary vaccines, including inactivated vaccines and genetically engineered subunit vaccines, such as pig vaccines for foot-and-mouth disease and blue ear disease.
    M903
  • HY-159751
    HS101 98%
    HS101 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants.
    HS101
  • HY-159752
    HS103 98%
    HS103 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants.
    HS103
  • HY-159753
    HS105 98%
    HS105 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants.
    HS105
  • HY-159754
    HS201 98%
    HS201 is a nucleotide extract that can be used as a vaccine adjuvant. HS201 can activate Toll-like receptors and trigger Th1 immune responses. HS201 is mainly used in inactivated vaccines for diseases such as foot-and-mouth disease.
    HS201
  • HY-159809
    Antibacterial agent 249 138801-72-6 98%
    Antibacterial agent 249 demonstrates broad-spectrum antimicrobial properties, effectively inhibiting the growth of Aspergillus niger, Bacillus subtilis, Pseudomonas albicans, Escherichia coli, and Staphylococcus aureus, while also exhibiting anti-inflammatory activity in vitro, making it a potential candidate for treating bacterial infections.
    Antibacterial agent 249
  • HY-159830
    Rivasterat 2446590-96-9 98%
    Rivasterat is a cholesterol-derived steroid with anti-inflammatory activity.
    Rivasterat
  • HY-159843
    Glasmacinal 2097822-02-9 98%
    Glasmacinal is a non-antibacterial macrolide agent with anti-inflammatory activity.
    Glasmacinal
  • HY-159853
    C14-A1 98%
    C14-A1 is an ionizable cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads.
    C14-A1
  • HY-159902
    KRN7000 analog 3 1384423-78-2 98%
    KRN7000 analog 3 (Compound 14),α-GalCer (HY-102022) analogue, is a iNKT agonist. KRN7000 analog 3 induces higher levels of IL-2 cytokine secretion (49.2-62.6 ng/mL) than a-GalCer (44.1 ng/mL) in mNK1.2 cells. KRN7000 analog 3 is promising for research of antitumor agents and vaccine adjuvants.
    KRN7000 analog 3
  • HY-159913
    AYK004-C1 3031612-92-4 98%
    AYK004-C1 is a TLR agonist. AYK004-C1 can be used to prepare immune adjuvants.
    AYK004-C1
  • HY-159914
    AYK004-B1 3031612-91-3 98%
    AYK004-B1 is a TLR7 agonist (EC50=0.2265 nM). AYK004-B1 can be used to prepare immune adjuvants.
    AYK004-B1
  • HY-159916
    AYK004 3031612-90-2 98%
    AYK004 is a TLR7/8 agonist that enhances immune responses by activating the TLR signaling pathway. AYK004 is an adenine derivative with a favorable hydrophilic-lipophilic balance, which improves the loading capacity and stability in immunoadjuvant systems such as liposomes, while reducing the side effects of the immunoadjuvant system in systemic immunity .
    AYK004
  • HY-159917
    PPL agonist-1 3040997-52-9 98%
    PPL agonist-1 is a highly selective Periplakin (PPL) agonist that increases cAMP levels by regulating PPL, thereby enhancing MITF expression and promoting melanin synthesis. Furthermore, PPL agonist-1 facilitates melanin production by regulating tryptophan metabolism. Compared to Ruxolitinib (HY-50856), PPL agonist-1 demonstrates superior efficacy. PPL agonist-1 holds potential for research into vitiligo treatment.
    PPL agonist-1
  • HY-159920
    PSB-22269 98%
    PSB-22269 is a GPR17 antagonist with a Ki value of 8.91 nM. PSB-22269 further demonstrated significant inhibitory effects in cAMP and G protein activation assays. Molecular docking studies revealed that the binding site of PSB-22269 contains positively charged arginine residues and a hydrophobic pocket. PSB-22269 provides a strategy to promote remyelination and holds promise for research in the field of multiple sclerosis.
    PSB-22269
Cat. No. Product Name / Synonyms Application Reactivity